Your browser doesn't support javascript.
loading
HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients.
Satapornpong, Patompong; Pratoomwun, Jirawat; Rerknimitr, Pawinee; Klaewsongkram, Jettanong; Nakkam, Nontaya; Rungrotmongkol, Thanyada; Konyoung, Parinya; Saksit, Niwat; Mahakkanukrauh, Ajanee; Amornpinyo, Warayuwadee; Khunarkornsiri, Usanee; Tempark, Therdpong; Wantavornprasert, Kittipong; Jinda, Pimonpan; Koomdee, Napatrupron; Jantararoungtong, Thawinee; Rerkpattanapipat, Ticha; Wang, Chuang-Wei; Naisbitt, Dean; Tassaneeyakul, Wichittra; Ariyachaipanich, Manasalak; Roonghiranwat, Thapana; Pirmohamed, Munir; Chung, Wen-Hung; Sukasem, Chonlaphat.
Afiliación
  • Satapornpong P; Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Pratoomwun J; Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand.
  • Rerknimitr P; Division of General Pharmacy Practice, Department of Pharmaceutical Care, College of Pharmacy, Rangsit University, Pathum Thani, Thailand.
  • Klaewsongkram J; Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Nakkam N; Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand.
  • Rungrotmongkol T; Department of Clinical Chemistry, Faculty of Medical Technology, Huachiew Chalermprakiet University, Samut Prakan, Thailand.
  • Konyoung P; The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand.
  • Saksit N; Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Mahakkanukrauh A; The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand.
  • Amornpinyo W; Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Khunarkornsiri U; King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
  • Tempark T; Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Wantavornprasert K; Biocatalyst and Environmental Biotechnology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
  • Jinda P; Program in Bioinformatics and Computational Biology, Graduated School, Chulalongkorn University, Bangkok, Thailand.
  • Koomdee N; Pharmacy Unit, Udon Thani Hospital, Udon Thani, Thailand.
  • Jantararoungtong T; Unit of Excellence on Pharmacogenomic Pharmacokinetic and Pharmacotherapeutic Researches (UPPER), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.
  • Rerkpattanapipat T; Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Wang CW; Division of Dermatology, Department of Internal Medicine, Khon Kaen Hospital, Khon Kaen, Thailand.
  • Naisbitt D; Pharmacy Unit, Udon Thani Hospital, Udon Thani, Thailand.
  • Tassaneeyakul W; Division of Dermatology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Ariyachaipanich M; The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand.
  • Roonghiranwat T; Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Pirmohamed M; Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand.
  • Chung WH; Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Sukasem C; Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand.
Front Immunol ; 12: 661135, 2021.
Article en En | MEDLINE | ID: mdl-34017337
ABSTRACT
HLA-B*1301 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*1301 and HLA-B*1302 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*1301 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67-198.21, p = 5.3447 × 10-7), SJS-TEN (OR = 36.00, 95% CI = 3.19-405.89, p = 2.1657 × 10-3), and DRESS (OR = 40.50, 95% CI = 6.38-257.03, p = 1.0784 × 10-5) as compared to dapsone-tolerant controls. Also, HLA-B*1301 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67-149.52, p = 2.8068 × 10-7) and Taiwanese (OR = 31.50, 95% CI = 4.80-206.56, p = 2.5519 × 10-3). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*1301 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*1301 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polimorfismo Genético / Piel / Antígenos HLA-B / Dapsona / Alelos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Tailandia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polimorfismo Genético / Piel / Antígenos HLA-B / Dapsona / Alelos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Front Immunol Año: 2021 Tipo del documento: Article País de afiliación: Tailandia